Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Sign in
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Clinical Topics
View All
Addiction
Anxiety
Bipolar Disorder
Depression
Difficult to Treat Depression
Emerging Approaches in Schizophrenia
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
View All
Catherine Miller, PharmD
JCP
Original Research
Long-Term Safety and Efficacy of Zuranolone in MDD
December 27, 2023
Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.
Andrew J. Cutler
,
Gregory W. Mattingly
,
Susan G. Kornstein
, et al
